Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Scott Wilke, MD (ucla)
Headshot of Scott Wilke
Scott Wilke

Description

Summary

This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned by chance to active or placebo group. Active group will be asked to take one 15 mg pill once daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active ingredients and has no affect on the body or mind. With the exception of the study drug, all other study activities between both groups will be identical. Subjects will use the assigned study drug two weeks before therapy and throughout the first 10 therapy treatments. A total of seven(7) visits will be required for screening, drug assignment, and completion of mood assessments. This study will enroll a total of 30 Subjects.

Official Title

*Full Title of the Submission: Psychostimulant Augmentation of Repetitive TMS (rTMS) for the Treatment of Major Depressive Disorder: A Randomized, Placebo-controlled Clinical Trial

Details

Keywords

Major Depressive Disorder, MDD, Randomized, rTMS, Randomized, rTMS, Depressive Disorder, Depression, Adderall, Adderall-XR

Eligibility

Location

  • UCLA Semel
    Los Angeles California 90025 United States

Lead Scientist at University of California Health

  • Scott Wilke, MD (ucla)
    Scott Wilke, M.D., Ph.D., holds the Patty and Greg Penske Family Endowed Chair.

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT04509102
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated